How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.

Related Videos

October 8, 2014

Approaching Unmet Clinical Needs in Polycythemia Vera

Dr. Michaelis discusses what approaches she takes for PV patients with unmet clinical needs such as recurrent thrombosis or hemorrhage. Supported through funding from Incyte

December 12, 2016

The Variability of HR+ Breast Cancer

Sunil Verma, MD, MSEd, FRCPC discusses treatment options for this type of cancer.